Subclinical Hypothyroidism: Treat or Watch?

Subclinical hypothyroidism (high TSH with normal free T4) doesn't always need treatment. Guidelines recommend levothyroxine when TSH is above 10, in pregnancy, or in symptomatic patients with TPO antibodies or goiter. For mild subclinical hypothyroidism (TSH 4.5–10) in older adults, the TRUST trial showed no symptom benefit.

What subclinical hypothyroidism is

Subclinical hypothyroidism is a biochemical diagnosis: TSH above the reference range with free T4 still within normal limits [C2][C3]. The thyroid is being pushed harder by the pituitary, but it's still keeping hormone output in the normal range. This is the early phase of thyroid failure in most patients.

It's common: roughly 5–10% of adults have subclinical hypothyroidism, with prevalence rising with age [C3][C5]. In women over 60, it can reach 15–20% [C3].

The clinical question is whether treating it improves anything that matters.

The TSH cutoff that drives decisions

Most guidelines divide subclinical hypothyroidism by TSH level [C2][C5][C6]:

• TSH 4.5–10 mIU/L (mild): The hardest decision. Most guidelines recommend individualized care, with reasons to treat including pregnancy, fertility planning, goiter, positive TPO antibodies, age under 65, or specific hypothyroid symptoms [C2][C5].
• TSH above 10 mIU/L (more severe): Treatment generally recommended because progression to overt hypothyroidism is more likely and cardiovascular risk may be elevated [C2][C5].

The 2019 BMJ Rapid Recommendation, integrating the TRUST trial and other evidence, made a weak recommendation against routine levothyroxine for adults with TSH 4.5–20 mIU/L outside of pregnancy, fertility planning, severe symptoms, or age under 30 [C6]. This was the strongest guideline pushback against over-treatment.

What the TRUST trial actually showed

The TRUST trial is the most important randomized evidence on this question. Stott and colleagues 2017 randomized 737 adults 65 and older with persistent subclinical hypothyroidism (TSH 4.6–19.99 mIU/L, free T4 normal) to either levothyroxine or placebo for at least 1 year [C1]. Levothyroxine was titrated to normalize TSH. Outcomes [C1]:

• Hypothyroid symptom score: No significant improvement with levothyroxine
• Tiredness score: No improvement
• Cardiovascular events: No difference
• Quality of life: No difference
• Cognitive function: No improvement

The very-elderly substudy (Mooijaart 2019) in patients 80+ likewise found no benefit [C8]. These results don't say treatment is harmful; they say that for many older adults with mild subclinical hypothyroidism, levothyroxine doesn't make them feel better or live longer.

When treatment is recommended despite the TRUST data

The 2014 ATA and 2013 ETA guidelines, along with the 2017 ATA pregnancy guideline, list specific scenarios where treatment is recommended even at mild TSH elevation [C2][C4][C5]:

1. Pregnancy or planning pregnancy. TSH above 2.5 in women trying to conceive or pregnant (especially TPO-positive) [C4]. See our levothyroxine-pregnancy article.
2. Infertility workup. Subclinical hypothyroidism is reversible, common, and worth treating in infertility care [C4].
3. TSH above 10 mIU/L. Most guidelines treat regardless of age [C2][C5].
4. Goiter or significant TPO antibodies. Progression to overt hypothyroidism is more likely [C2][C5].
5. Hypothyroid symptoms attributable to the disease. Cautious trial of levothyroxine for 3–6 months with discontinuation if symptoms don't improve is reasonable [C2][C5].
6. Younger adults (under 65–70). Some guidelines lean toward treatment, recognizing the TRUST data was in older adults [C5][C6].

When watchful waiting is reasonable

The pattern that emerges from guidelines [C2][C5][C6]:

• Older adults (65+) with TSH 4.5–10 and no specific reasons to treat. Repeat TSH in 3–6 months. Many patients normalize spontaneously [C3].
• Asymptomatic patients with mild subclinical hypothyroidism. Watchful waiting with annual TSH is appropriate [C5][C6].
• Recent illness or recovery period. TSH can be transiently elevated; repeat after recovery before committing to long-term treatment [C2][C3].

What progression actually looks like

Roughly 2–5% of patients with subclinical hypothyroidism per year progress to overt hypothyroidism [C3]. Risk factors for progression [C3][C5]:

• Higher initial TSH (above 6 versus near 5)
• TPO antibody positivity
• Female sex
• Goiter on physical exam

Antibody-positive patients can have annual progression rates of 4% or more, versus 1–2% in antibody-negative patients [C3].

Practical guidelines

1. Confirm before treating. A single elevated TSH should be confirmed with a repeat test in 2–3 months before any treatment decision [C2][C3]. Many isolated elevations resolve.
2. Order TPO antibodies if TSH is consistently mildly elevated. Antibody status changes risk and surveillance [C2][C5].
3. Treat pregnancy and fertility scenarios actively. TSH targets are tighter in this population, and the TRUST data doesn't apply [C4].
4. For older adults with TSH 4.5–10, watchful waiting is reasonable. TRUST showed no benefit; repeat TSH every 6–12 months [C1][C6][C8].
5. If treated, the goal is a normal TSH at the lowest effective dose. Over-treatment carries cardiovascular and bone risks, especially in older adults [C2].
6. Don't pursue T3 or NDT for subclinical hypothyroidism. Standard levothyroxine if treatment is chosen [C2].

Frequently asked questions

Should I take levothyroxine for a TSH of 5? Probably not, depending on context. If you're under 30, planning pregnancy, antibody-positive, symptomatic, or have a goiter — discuss treatment [C2][C5]. If you're 65+, asymptomatic, and antibody-negative, repeat the test and consider watchful waiting [C1][C6].

Will treatment help my fatigue? The TRUST trial in older adults found no improvement in fatigue from treating mild subclinical hypothyroidism [C1]. In younger adults with TPO antibodies, a 3–6 month trial may be reasonable, with discontinuation if no benefit [C5].

Can subclinical hypothyroidism resolve on its own? Yes. A significant minority of patients with mildly elevated TSH normalize spontaneously over 1–2 years, especially if antibody-negative [C3].

Does subclinical hypothyroidism increase heart risk? There's an association at higher TSH levels (especially above 10) but the TRUST trial didn't show that treating mild subclinical hypothyroidism reduces cardiovascular events [C1]. The picture is age-dependent and complicated [C5].

My TSH is 6 and I want to get pregnant. What now? ATA pregnancy guidelines recommend starting levothyroxine to reach TSH below 2.5 mIU/L before conception, especially if you're TPO-positive [C4]. See our levothyroxine-pregnancy article.

Can I do anything besides medication? Confirm the diagnosis with a repeat test. Adequate iodine intake (not megadose), selenium from food, treating sleep apnea or vitamin B12 deficiency, and managing weight all support general thyroid health, but no lifestyle intervention has been shown to reverse subclinical hypothyroidism on its own [C5][C7].

Bottom line

Subclinical hypothyroidism isn't a single diagnosis to "treat or not" — it's a spectrum with treatment thresholds shaped by TSH level, age, symptoms, antibody status, and pregnancy plans [C2][C5][C6]. The TRUST randomized trial showed no symptom benefit from levothyroxine in older adults with mild subclinical hypothyroidism [C1][C8]. Guidelines recommend treatment for TSH above 10, in pregnancy or fertility planning, with positive antibodies plus symptoms, or with goiter [C2][C4][C5]. For mild cases in older adults with no specific reason, watchful waiting with periodic TSH is a defensible choice [C1][C6]. The decision belongs with your endocrinologist or primary-care doctor, not a one-size-fits-all rule.

Sources

1. [C1] Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376(26):2534–2544. PubMed: 28402245
2. [C2] Jonklaas J et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670–1751. PubMed: 25266247
3. [C3] Surks MI et al. Subclinical thyroid disease: scientific review and guidelines. JAMA. 2004;291(2):228–238. PubMed: 14722150
4. [C4] Alexander EK et al. 2017 ATA Guidelines for Thyroid Disease During Pregnancy. Thyroid. 2017;27(3):315–389. PubMed: 28056690
5. [C5] Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013;2(4):215–228. PubMed: 24783053
6. [C6] Bekkering GE, Agoritsas T, Lytvyn L, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline (BMJ Rapid Recommendations). BMJ. 2019;365:l2006. PubMed: 31088853
7. [C7] American Thyroid Association. Hypothyroidism — Patient Information. thyroid.org
8. [C8] Mooijaart SP, Du Puy RS, Stott DJ, et al. Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism. JAMA. 2019;322(20):1977–1986. PubMed: 31664429

---

For educational purposes only. Not medical advice. Always consult your healthcare provider.